Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947529 · ClinicalTrials.gov registry record · Phase 4
Tranexamic Acid Use in Acute Hip Fractures
A Phase 4 study, sponsored by Carilion Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 113
- Enrollment target
NCT02947529 is a Phase 4 study that has completed, run by Carilion Clinic. The registered enrollment target is 113 participants.
The verdict
NCT02947529, a Phase 4 study, has completed, sponsored by Carilion Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 113 participants
- Enrollment target
Study Summary
BACKGROUND: Tranexamic acid (TXA) has been used widely for the reduction of post operative blood loss for various orthopaedic procedures including but not limited to total hip arthroplasty and total knee arthroplasty. A recent multihospital meta-analysis conducted in 2013 showed that patients who received TXA showed a significant reduction in post-operative transfusion (20.1% to 7.7%). The procedures the investigators will be evaluating are the intramedullary nail for intertrochanteric fracture and hip hemiarthroplasty. These procedures are similar to the total hip or knee replacement in that they can result in significant blood loss that requires a post operative transfusion. STUDY PURPOSE: To determine the efficacy of TXA to decrease the rate of post-operative transfusion for acute hip fractures repaired with the following two methods, intramedullary nailing for intertrochanteric fracture and hemiarthroplasty. METHODS: The model for the study is a prospective randomized control trial. Patients will be placed in one of two arms of the study after passing our inclusion criteria. The arms will be for either the intramedullary nailing for intertrochanteric fracture or for hemiarthroplasty. These two categories will be subdivided into those receiving TXA and those not receiving TXA. The patients in each category will have standard post-operative care and laboratory testing. The investigators will record the patients in either arm of the study, whether it be no TXA or TXA, who require post-operative transfusion within 1 week of the operation.
Interventions
- OTHER Placebo
- DRUG Tranexamic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2015-08 |
| Est. Completion | 2022-05-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947529
The ClinicalTrials.gov registry entry for NCT02947529 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carilion Clinic, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02947529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947529 about?
NCT02947529 is a clinical study titled "Tranexamic Acid Use in Acute Hip Fractures". BACKGROUND: Tranexamic acid (TXA) has been used widely for the reduction of post operative blood loss for various orthopaedic procedures including but not limited to total hip arthroplasty and total knee arthroplasty. A recent multihospital meta-analysis conducted in 2013 showed that patients who re...
What is the current status of trial NCT02947529?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 113 participants. The study started on 2015-08. Estimated completion is 2022-05-22.
What interventions are being tested in trial NCT02947529?
The interventions under investigation include: Placebo (OTHER), Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT02947529?
This trial is sponsored by Carilion Clinic, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.